Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immune Therapeutics Inc (IMUN)

Immune Therapeutics Inc (IMUN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 7,780
  • Shares Outstanding, K 83,658
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,540 K
  • 60-Month Beta 0.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade IMUN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.04
  • Most Recent Earnings $-0.04 on 11/14/22
  • Next Earnings Date 11/13/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0720 +29.17%
on 10/11/23
0.1000 -7.00%
on 10/11/23
+0.0220 (+30.99%)
since 09/18/23
3-Month
0.0668 +39.22%
on 09/18/23
0.9000 -89.67%
on 07/24/23
-0.7068 (-88.37%)
since 07/18/23
52-Week
0.0668 +39.22%
on 09/18/23
1.3000 -92.85%
on 11/01/22
-1.2670 (-93.16%)
since 10/18/22

Most Recent Stories

More News
Immune Therapeutics Appoints Chief Financial Officer and Chief Operating Officer

ORLANDO, FL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company...

OTC.VN : 0.350 (unch)
IMUN : 0.0930 (-7.00%)
Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer

ORLANDO, FL, July 22, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC Pink: IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company...

OTC.VN : 0.350 (unch)
IMUN : 0.0930 (-7.00%)
Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone

FORT COLLINS, Colo., April 27, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a leading biopharmaceutical company creating...

STAB : 0.0002 (unch)
IMUN : 0.0930 (-7.00%)
Immune Therapeutics Announces Restructuring Plan

Orlando, Florida , June 04, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTC-PINK: IMUN) (the "Company") announced today that the Company has received and signed a non-binding term sheet to enter...

IMUND : 5.2500 (-8.54%)
IMUN : 0.0930 (-7.00%)
Immune Therapeutics Announces Financing and Debt Restructuring Plan

Orlando, Florida, June 02, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTC-PINK: IMUND) (the "Company") announced today that the Company has received and signed a non-binding term sheet to enter...

IMUN : 0.0930 (-7.00%)
IMUND : 5.2500 (-8.54%)
Immune Therapeutics FINRA Approval for 1:1000 Reverse Stock Split

Orlando, Florida , May 11, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTC-PINK: IMUN) (the "Company") announced today that FINRA has processed a reverse split of 1-for 1,000 of the issued and...

IMUN : 0.0930 (-7.00%)
Immune Therapeutics Inc. Spinoff Cytocom, Inc. to Participate in Biotech Showcase and H.C. Wainwright BioConnect 2021 During “J.P. Morgan Week 2021”

WINTER PARK, FL, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (Ticker: IMUN) announced today that Cytocom, Inc., a company that spun-off from Immune in 2014, is participating in Biotech...

IMUN : 0.0930 (-7.00%)
Immune Therapeutics, Inc. Announces Signing of Definitive Merger Agreement Between Cytocom and Cleveland BioLabs

Merger to create a single public company focused on the development and commercialization of immunotherapies for oncology, infectious disease, inflammation and auto-immune mediated conditions

IMUN : 0.0930 (-7.00%)

Business Summary

Forte Biotechnology Intl Corp is a biotechnology company. Its goal is to acquire late stage modulator drugs and immune modulator biopharmaceuticals for cancer, chronic inflammation, pain and neurodegenerative disease in companion pets. Forte Biotechnology Intl Corp, formerly known as Immune Therapeutics...

See More

Key Turning Points

3rd Resistance Point 0.0930
2nd Resistance Point 0.0930
1st Resistance Point 0.0930
Last Price 0.0930
1st Support Level 0.0930
2nd Support Level 0.0930
3rd Support Level 0.0930

See More

52-Week High 1.3000
Fibonacci 61.8% 0.8289
Fibonacci 50% 0.6834
Fibonacci 38.2% 0.5379
Last Price 0.0930
52-Week Low 0.0668

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar